Evaluation of sequential testing strategies using non-amplified and amplified methods for detection of Chlamydia trachomatis in endocervical and urine specimens from women.
Nucleic acid amplification tests (NAAT) are more sensitive than other methods for the diagnosis of Chlamydia trachomatis (CT) genital infections. Two unique sequential testing strategies that employed two different commercial NAAT methods to detect CT in a population of women with widely varying infection risk were evaluated. Specimens from 504 women aged 15 to 75 years were studied. Two endocervical swabs and a urine sample were collected from each woman. One swab was initially tested using the Access enzyme immunoassay (EIA) (Beckman). An aliquot from the EIA extraction was subsequently amplified using the COBAS AMPLICOR CT assay (PCR) (Roche). The second swab was initially tested using the PACE 2 CT hybridization assay (Gen-Probe). An aliquot was pipetted off prior to performing the PACE 2 assay and also amplified using the AMP-CT assay (TMA) (Gen-Probe). Urine samples were tested for CT using both NAAT methods. True CT infections were defined as any woman that was confirmed to be positive on both NAAT results from endocervical swabs. The results of all other CT assays were compared against this expanded gold standard. 28 women were confirmed to have CT infection giving an overall prevalence of 5.6%; low-risk women had a rate of 1.3% while high-risk women had a rate of 9.8%. NAAT methods have a higher sensitivity for detecting CT cervicitis when swabs are tested compared to urine. The positive predictive value of NAAT is decreased when testing low risk women. Limited automation makes it difficult to test a high volume of samples (i.e., > 100 swabs and/or urines) using either of these NAAT methods and continue to provide same day results. Laboratories performing CT testing must define the female population served so that appropriate diagnostic strategies can be employed.